Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
5.36
-0.15 (-2.72%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Verrica Pharmaceuticals Revenue
Verrica Pharmaceuticals had revenue of $5.02M in the quarter ending March 31, 2026, with 46.06% growth. This brings the company's revenue in the last twelve months to $37.16M, up 417.63% year-over-year. In the year 2025, Verrica Pharmaceuticals had annual revenue of $35.58M with 370.22% growth.
Revenue (ttm)
$37.16M
Revenue Growth
+417.63%
P/S Ratio
2.48
Revenue / Employee
$488,961
Employees
76
Market Cap
92.08M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.58M | 28.01M | 370.22% |
| Dec 31, 2024 | 7.57M | 2.44M | 47.66% |
| Dec 31, 2023 | 5.12M | -3.91M | -43.27% |
| Dec 31, 2022 | 9.03M | -2.97M | -24.73% |
| Dec 31, 2021 | 12.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 150.71M |
| Fortress Biotech | 66.16M |
| Gossamer Bio | 55.54M |
| NeurAxis | 4.28M |
| Rallybio | 858.00K |
| NeOnc Technologies Holdings | 39.99K |
VRCA News
- 11 hours ago - Verrica Pharmaceuticals reports Q2 EPS (62c), consensus (47c) - TheFly
- 12 hours ago - Verrica Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 12 hours ago - Verrica Pharmaceuticals Earnings release: Q2 2026 - Filings
- 12 hours ago - Verrica Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 7 days ago - Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 - GlobeNewsWire
- 16 days ago - Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel - GlobeNewsWire
- 6 weeks ago - Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts